CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms

af Meyer, Sara C., Keller, Matthew D., Chiu, Sophia, Koppikar, Priya, Guryanova, Olga A., Rapaport, Franck, Xu, Ke, Manova, Katia, Pankov, Dmitry, O’Reilly, Richard J., Kleppe, Maria, McKenney, Anna Sophia, Shih, Alan H., Shank, Kaitlyn, Ahn, Jihae, Papalexi, Eftymia, Spitzer, Barbara, Socci, Nick, Viale, Agnes, Mandon, Emeline, Ebel, Nicolas, Andraos, Rita, Rubert, Joëlle, Dammassa, Ernesta, Romanet, Vincent, Dölemeyer, Arno, Zender, Michael, Heinlein, Melanie, Rampal, Rajit, Weinberg, Rona Singer, Hoffman, Ron, Sellers, William R., Hofmann, Francesco, Murakami, Masato, Baffert, Fabienne, Gaul, Christoph, Radimerski, Thomas, Levine, Ross L.
Udgivet i Cancer Cell (2015)